EP1752768B1 - Method of detecting hepatitis b virus - Google Patents

Method of detecting hepatitis b virus Download PDF

Info

Publication number
EP1752768B1
EP1752768B1 EP05741615A EP05741615A EP1752768B1 EP 1752768 B1 EP1752768 B1 EP 1752768B1 EP 05741615 A EP05741615 A EP 05741615A EP 05741615 A EP05741615 A EP 05741615A EP 1752768 B1 EP1752768 B1 EP 1752768B1
Authority
EP
European Patent Office
Prior art keywords
hbv
treatment
antigens
sample
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP05741615A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1752768A1 (en
EP1752768A4 (en
Inventor
Chiharu ADVANCED LIFE SCIENCE INSTITUTE Inc OHUE
Noboru ADVANCED LIFE SCIENCE INSTITUTE Inc MAKI
Tatsuji ADVANCED LIFE SCIENCE INST. Inc. KIMURA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Life Science Institute Inc
Original Assignee
Advanced Life Science Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Life Science Institute Inc filed Critical Advanced Life Science Institute Inc
Publication of EP1752768A1 publication Critical patent/EP1752768A1/en
Publication of EP1752768A4 publication Critical patent/EP1752768A4/en
Application granted granted Critical
Publication of EP1752768B1 publication Critical patent/EP1752768B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B

Definitions

  • the present invention relates to a method for treatment of a sample containing hepatitis B virus (hereinafter, referred to as "HBV") to detect or quantify HBV antigens in blood with high sensitivity and a method for detection or quantification of HBV antigens using said method for treatment.
  • HBV hepatitis B virus
  • HBV is the virus identified for the first time as a causative virus of post-transfusion hepatitis and HBV infection occurs through blood transfusion at the time of surgery. Accordingly, for screening of blood for transfusion, it is extremely important to make diagnosis of the presence or absence of HBV infection in blood.
  • diagnostic methods for this HBV infection there is a method for detection of antibody to HBV in a sample, a method for detection of HBV antigens, or a method for detection of HBV genes.
  • the method for detection of HBV genes includes a nucleic acid amplification test (NAT) and a DNA probe test, which are currently widely used in clinical setting. Further, attention is directed to a relation between the amount of HBVDNA and the pathosis of HBV carrier by virtue of widespread use of the NAT method, and the NAT method has come to be mainly used for monitoring after treatment with an antiviral drug.
  • NAT nucleic acid amplification test
  • DNA probe test a DNA probe test
  • NAT methods such as PCR method and TMA method are highly sensitive methods for detecting gene fragments.
  • HBV genomic DNA when HBV genomic DNA is extracted from a sample, these methods require a treatment time as long as two hours in the manual method as well as include a plural process steps, and so forth, which is complicated.
  • the complexity of this process increases chances of contamination and increases the possibility of having false positive samples.
  • technical skills are needed to obtain consistent assay values.
  • DNA primers must match the target gene, several kinds of primers need to be used, which gives rise to a problem that the cost per test becomes high as compared with that of immunoassays.
  • HBV antigen tests a method for detection of HBs antigen has been conventionally used for blood screening and a method for measurment of HBe antigen has been widely used for a proliferation marker of HBV.
  • HBV core antigen HBc antigen
  • Usuda et al. Journal of Virological Methods, 72, 95-103, 1998 ) developed a method for detection of HBc antigen in serum using monoclonal antibodies having specificity for HBV core (HBc) antigen and showed that the method was clinically useful similarly to the above-described NAT method for detection of viral genome.
  • This HBc antigen detection system is relatively tolerant to contamination because amplification procedures are not included in the detection process.
  • Oshihara et al. have developed a method in which HBc antigen is assayed by means of treatment with an alkali, treatment with pronase, and addition of Nonidet P40 (NP-40) that is a nonionic surfactant and mercaptoethanol without performing the treatment with anti-HBs polyclonal antibodies (Japanese Patent Laid-Open No. 8-50133 ).
  • NP-40 Nonidet P40
  • this method indicates low sensitivity and the concentration of HBc antigen in the detection limit is equivalent to 2.2 pg/ml of the concentration of HBV-DNA which is estimated at the order of 10 5 to 10 6 copies/ml.
  • HBcr antigens HBV core-related antigens
  • HBe antigen and HBc antigen International Publication WO 02/14871 A1
  • HBVp22cr antigen a method for assay of HBV core-related antigens to allow simultaneous assay of HBe antigen and HBc antigen
  • HBVp22cr antigen a method for assay of HBV core-related antigens (HBcr antigens) to allow simultaneous assay of HBe antigen and HBc antigen
  • HBVp22cr antigen International Publication WO 04/22585 A1
  • These methods are more sensitive than the methods for detection of HBc antigen but indicate still an unsatisfactory sensitivity when compared with the methods of measurement of HBV genome.
  • EP-0967484-A1 discloses a method for treating a virus-containing sample, characterized by treatment of a virus containing sample with a treatment solution containing (1) an anionic surfactant and (2) an amphoteric surfactant, nonionic surfactant or protein denaturant and a method for treating a virus-containing sample with a treatment solution containing (1) a chaotropic ion and (2) an acidifying agent.
  • Non-Patent Document 1 Journal of Virological Methods, 72, 95-103, 1998
  • Immunoassays can be performed easily and at a low cost; however, the current method for assay of HBe antigen that is used as a proliferation marker cannot measure HBe antigen occurring as immune complexes in the presence of anti-HBe antibodies. Further, the methods for assay of HBc antigen are not applied in clinical studies owing to the complexity of pretreatment as described above and insufficiency of sensitivity, although the amounts of HBc antigen correlate with the amounts of HBV DNA.
  • pretreatment of a sample is carried out using a surfactant and heat (from 56 to 70°C) to disrupt antibodies and virus particles, and then HBV core-related antigens or HBV p22cr antigens are measured.
  • a surfactant and heat from 56 to 70°C
  • HBV core-related antigens or HBV p22cr antigens are measured.
  • these methods also need to treat a sample off-board and the adaptation to the full automation is difficult.
  • the object of the present invention is to provide a pretreatment method for assay of HBV core-related antigens (HBe and HBc antigens), HBV p22cr antigen, and the like even in the presence of anti-HBV antibodies for screening of hepatitis B, monitoring in the treatment of patients with chronic hepatitis B, and so forth, and an assay method with the use thereof.
  • the object of this disclosure is to provide a system for detection of HBV antigens that can be easily applied to a mass treatment system such as automation by simple pretreatment in shorter time.
  • the present inventors focused attention on (a) a method for treatment of a sample containing HBV that allows HBV antigens in the sample to be converted into a state suitable for detection with a probe only by a simple procedure in a short time and (b) a method for treatment that allows antibodies against HBV antigens originating from a host that compete with a probe for capture or detection to be simultaneously inactivated by the simple procedure in a short time in order to detect HBV antigens in the sample.
  • the present inventors found that, for assay of HBV antigens, not only can HBV antigens present in a sample be released from virus particles or immune complexes but also human antibodies against HBV present in the sample are inactivated by (c) treatment of the sample with an acidifying agent and (d) treatment with a surfactant, a protein denaturant, and a reducing agent in addition to the former treatment, and that (e) a sample most suitable for an immunoassay with a probe such as antibody can be provided by the use of the treatment method.
  • the present inventors found it possible to provide (f) a step of treating a sample with a treatment agent that releases HBV antigens present in the sample containing HBV antigens from the virus particles and that also simultaneously inactivates the human antibodies against HBV present in the sample, a method for detection and quantification of HBV antigens by an immunoassay involving the treatment step, and (g) an HBV antigen assay kit containing the treatment agent, and achieved the present invention based on these findings.
  • the present invention it becomes possible to release HBV antigens easily in a short time from the virus particles in a state suitable for an immunoassay method in which an antigen is detected with a probe such as antibody as well as to inactivate antibodies against HBV antigens. Further, it becomes possible to detect and quantify HBV antigens easily in a short time with high sensitivity by treating a sample containing HBV according to the method described in the present invention and subjecting to the immunoassay method in which an antigen is detected with a probe such as antibody.
  • the present invention it is possible to solve the problem of precipitation caused by acid treatment by the use of the surfactant and the like in addition to the acidifying agent, disrupt protein efficiently, release viral antigens with ease in a short time, and bring about a remarkably excellent sensitivity-enhancing effect.
  • Figure 1 is a graph showing the result of the effect depending on the concentration of an acidifying agent (hydrochloric acid) in sample treatment.
  • Samples used in the method for treatment of a sample containing HBV antigens according to the present invention include biological fluids such as whole blood, plasma, serum, urine, saliva, and cerebrospinal fluid, liver tissues, and the like.
  • the infectious particle of HBV is thought to be Dane particle having a structure with a diameter of 42 nm.
  • the envelope lipoproteins are HBs antigens, and HBc antigens form an inner nucleocapsid (core particle) with a diameter of 27 nm.
  • HBV p22cr antigen that forms an HBV nucleocapsid-like particle, and this molecule is thought to form a core-like particle and have HBs antigen on its outside.
  • hepatitis B The diagnosis of hepatitis B is generally performed by detecting HBs antigen or HBe antigen.
  • the measurement of these antigens do not accurately reflect the time of the infection and the amount of infectious particles. For this reason, it is necessary to determine HBc antigen, HBV core-related antigens, and HBV p22cr antigen that make up the virus particle or the virus-like particle.
  • HBc antigen and p22cr antigen form the virus particle and HBe antigen and the like forms immune complexes with anti-HBV antibodies.
  • HBe antigen, and HBV p22cr antigen among these antigens it is necessary to I) allow HBc antigen and HBV p22cr antigen not only to be released from HBV particles by disrupting the HBV particles but also to be converted to their monomer forms as much as possible, II) inactivate or remove antibodies, originating from a host, against HBc antigen and HBe antigen of HBV, and III) release HBc antigen, HBe antigen, and HBV p22cr antigen from interactions with blood components other than the antibodies against the HBV antigens.
  • the antibodies against the HBV antigens can be removed by centrifugation and affinity chromatography, treatment steps increase, and therefore, it seems desirable to carry out the inactivation.
  • a maximum release of HBc antigen, HBe antigen, and HBV p22cr antigen, contained in a limited amount of sample in a detection system, in their monomer states from HBV particles, antibodies against HBV antigens, and other blood components results in an increase of the number of the antigen molecules that can react with a probe. It is important to maximally release the antigens in their monomer states by a short-time and simple sample treatment, thereby enhancing their reactivity with a probe.
  • an alkaline treatment, an acid treatment, and the like are known.
  • certain serum-derived proteins and the like are irreversibly denatured and precipitation or cloudiness occurs in certain cases. Therefore, when a sample after treated with an acid is pipetted, trouble such as clogging often occurs.
  • precipitates entangling denatured proteins and the like may adsorb to a carrier or solid phase linked with a probe such as antibody to capture a target antigen, resulting in a false positive.
  • the target antigen is entangled in those precipitates and the amount of the antigen that can be bound to the probe is decreased, thereby presenting a problem of sensitivity reduction.
  • the present invention makes it possible to achieve prevention of precipitation and cloudiness caused by the acid treatment, prevention of false positive, and enhancement of sensitivity by adding another substance to an acidifying agent.
  • the acidifying agent hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, trichloroacetic acid are appropriate.
  • the concentration of the acidifying agent at the treatment is preferably 0.05 N or higher and 1 N or lower, and further preferably from 0.25 N to 1 N.
  • a sample added acidifying agent is treated at pH 2.5 or lower, and in most samples at pH 2.0 or lower.
  • One of the substances added to the acidifying agent in the treatment agent includes a surfactant.
  • Various surfactants are known to have an activity to disrupt a higher structure of protein and exert effects such as disruption of viral particle membrane, denaturation of antibodies, and solubilization of insoluble proteins.
  • a conformational epitope of a target antigen is also disrupted, resulting in weakening of binding to a probe such as antibody to capture the antigen, which presents a serious problem of sensitivity reduction.
  • the denaturing activity of the surfactant may of ten be reversible, and a temporarily denatured structure is sometimes returned to the original structure by reducing the concentration of the surfactant by means of dilution or dialysis. Therefore, the antibodies originating from a sample may compete with a probe for measurement, and as the result, it is apparent that sensitivity may be reduced.
  • the addition of the surfactant has such an ambivalent nature described above.
  • Surfactants are classified into various groups according to their structures and properties. For example, there are ionic and nonionic surfactant, and the ionic surfactant further include anionic, cationic, amphoteric surfactants, and the like.
  • the present inventors have found that the problem associated with the acid treatment such as occurrence of precipitates and the problem associated with the surfactant treatment such as reactivation of antibodies in a sample can be solved by combining the acidifying agent with the cationic surfactant, and that the combination shows a significant enhancement effect in sensitivity with respect to the detection of HBV antigens.
  • the present inventors have found that a striking effect is obtained by using a cationic surfactant having a straight chain alkyl group of 12 or more carbon atoms and a tertiary amine or a quaternary ammonium salt within the same molecule.
  • a nonionic surfactant e.g. polyoxyethylene iso- octylphenyl ethers such as Triton X-100 or polyoxyethylene sorbitan alkyl esters such as Tween 20, the addition of a protein denaturant such as urea or thiourea, and the addition of a reducing agent such as cysteine, cysteamine, dimethyl- aminoethanethiol, diethylaminoethanethiol, diisopropyl- aminoethanethiol, or dithiothreitol to the treatment agent containing the acidifying agent and the surfactant are more preferable.
  • a nonionic surfactant e.g. polyoxyethylene iso- octylphenyl ethers such as Triton X-100 or polyoxyethylene sorbitan alkyl esters such as Tween 20
  • a protein denaturant such as urea or thiourea
  • a reducing agent
  • the present disclosure provides the method for treatment of a sample containing HBV characterized in that release of HBV antigens and inactivation of antibodies bound to HBV antigens are carried out by treating a sample containing HBV with a treatment agent containing an acidifying agent selected from the group of hydrochloric acid, sulfuric acid, trifluoroacetic acid and trichloroacetic acid, and a cationic surfactant having an alkyl group and a tertiary amine or a quaternary ammonium salt within the same molecule, a nonionic surfactant, and further a protein denaturant, and a reducing agent.
  • a treatment agent containing an acidifying agent selected from the group of hydrochloric acid, sulfuric acid, trifluoroacetic acid and trichloroacetic acid, and a cationic surfactant having an alkyl group and a tertiary amine or a quaternary ammonium salt within the same molecule, a nonionic sur
  • amphoteric surfactant having an alkyl group and a tertiary amine or a quaternary ammonium salt within the same molecule
  • N-dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate N-tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate
  • N-octadecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate and the like are appropriate.
  • decyltrimethylammonium chloride dodecyltrimethylammonium chloride, tetradecyltrimethylammonium chloride, hexadecyltrimethylammonium chloride, decyltrimethylammonium bromide, dodecyltrimethylammonium bromide, tetradecyltrimethylammonium bromide, hexadecyltrimethylammonium bromide
  • lauryl pyridinium chloride, tetradecyl pyridinium chloride, cetyl pyridinium chloride, and the like are appropriate.
  • the concentration at the treatment of such an cationic surfactant having an alkyl group and a tertiary amine or a quaternary ammonium salt within the same molecule is preferably 0.1% or higher and 15% or lower, further preferably from 0.5% to 10%.
  • nonionic surfactant added to the acidifying agent and the cationic surfactant having an alkyl group and a tertiary amine or a quaternary ammonium salt within the same molecule polyoxyethylene isooctylphenyl ethers such as Triton X-100, polyoxyethylene nonylphenyl ethers such as NP40 or polyoxyethylene sorbitan alkyl esters such as Tween 80 are appropriate, and their concentrations at the treatment are preferably 1% or higher and 7.5% or lower, further preferably 1% or higher and 5% or lower.
  • urea, thiourea, and the like are appropriate, and their concentrations at the treatment are preferably 0.5 M or higher, further preferably 1 M or higher and 8 M or lower.
  • concentrations at the treatment are preferably 0.5 M or higher, further preferably 1 M or higher and 8 M or lower.
  • concentrations up to 10 M it is possible to use at concentrations up to 10 M.
  • cysteine, cysteamine, dimethylaminoethanethiol, diethylaminoethanethiol, diisopropylaminoethanethiol, dithiothreitol, and the like are appropriate, and their concentrations at the treatment are preferably 0.25 mM or higher and 1000 mM or lower, further preferably 1.5 mM or higher and 200 mM or lower.
  • an additional substance added to the treatment agent includes a protein denaturant such as urea.
  • a protein denaturant such as urea.
  • Such a protein denaturant is known to have an activity to partially disrupt protein conformation by weakening hydrogen bonds, and it can disrupt viral particle membrane and denature antibodies against a target antigen in a sample. It has also an effect of solubilizing insoluble precipitates, for example, solubilizing a recombinant protein expressed in E. coli from its inclusion body that is an insoluble fraction.
  • a conformational epitope of the target antigen is also disrupted, resulting in weakening of binding to a probe such as antibody to capture the antigen, which presents a problem of sensitivity reduction.
  • the denaturing activity of the protein denaturant such as urea may often be reversible, and a temporarily denatured structure is sometimes returned to the original structure by reducing the concentration of the protein denaturant by means of dilution or dialysis. This results in a state in which antibodies originating from a sample may compete with a probe for measurement, and as the result, it is apparent that sensitivity may be reduced.
  • the addition of the protein denaturant such as urea has such an ambivalent nature described above.
  • the present inventors have perfected another treatment by finding that the problem associated with the acid treatment such as occurrence of precipitates and the problem associated with the protein denaturant treatment such as reactivation of antibodies in a sample can be solved by combining the acid treatment with the protein denaturant treatment.
  • the present inventors have found that the formation of precipitates by the acid treatment can be significantly decreased by adding urea, one of protein denaturants, at 1 M or higher concentration at the treatment.
  • urea one of protein denaturants
  • concentration of the protein denaturant at the treatment is preferably 1 M or higher, further preferably 1.5 M or higher and 8 M or lower.
  • a nonionic surfactant e. g.
  • polyoxyethylene isooctylphenyl ethers such as Triton X100 and polyoxyethylene sorbitan alkyl esters such as Tween 20, to the treatment agent containing the acidifying agent and the protein denaturant exerts an effect on enhancement of sensitivity.
  • a reducing agent to the treatment agent containing the acidifying agent and the protein denaturant.
  • the present invention provides a method for treatment of a sample containing hepatitis B virus (HBV) characterized in that release of HBV antigens and inactivation of antibodies bound to HBV antigens are carried out by treating a sample containing HBV with a treatment agent containing (1) an acidifying agent selected from the group of hydrochloric acid, sulfuric acid, trifluoroacetic acid and trichloroacetic acid, and (2) cationic surfactant having an alkyl group of 12 or more carbon atoms and a tertiary amine or a quaternary ammonium salt within the same molecule.
  • HBV hepatitis B virus
  • the treatment temperature in the method for treatment of a sample containing HBV according to the present invention may be high, but preferably from 20°C to 50°C, further preferably from 25°C to 42°C.
  • the treatment agent combined with the acidifying agent in the present invention is the cationic surfactant having an alkyl group of 12 or more carbon atoms and a tertiary amine or a quaternary ammonium salt within the same molecule.
  • a treatment agent combined with the acidifying agent there is, for example, the amphoteric surfactant having an alkyl group and a tertiary amine or a quaternary ammonium salt within the same molecule, the cationic surfactant having an alkyl group and a tertiary amine or a quaternary ammonium salt within the same molecule, the protein denaturant, the nonionic surfactant, the reducing agent, or an anionic surfactant.
  • the method for immunological detection of HBV antigens comprises the steps of releasing HBV antigens and inactivating antibodies that are binding to HBV antigens by allowing HBV-containing samples to come in contact with the treatment agent containing the acidifying agent and the surfactant according to any one of claims 1 to 5 (step 1) and detecting the HBV antigens with the use of a probe that binds to the HBV antigens (step 2).
  • the probe used for the detection for example, an antibody that specifically binds to an HBV antigen, any molecule that exhibits a high affinity for HBV antign can be used. It is desirable that one of the probes to capture HBV core-related antigens in a sample that has been treated in the step 1 is, for example, a monoclonal antibody such as HB44, HB114, or HB61.
  • the probe referred herein is, for example, a polyclonal antibody obtained by immunizing an experimental animal such as mouse, rat, guinea pig, rabbit, chicken, goat, sheep, or bovine, a monoclonal antibody produced by a hybridoma that is obtained by fusing the spleen cells and the like isolated from an immunized individual and myeloma cells or a monoclonal antibody produced by a cell line that is obtained by immortalizing spleen cells from an immunized individual or leukocytes in the blood using EB virus, a polyclonal antibody produced by human, chimpanzee, or the like that is infected with HBV, or a molecule exhibiting high specificity and affinity to HBV antigen that is produced by recombinant technology from a variable region gene fragment obtained from a cDNA or a chromosomal DNA of immunoglobulin of mouse, human, or the like, or a variable region gene fragment constructed by combining part of cDNA or
  • an HBV antigen forms an immune complex with the monoclonal antibody as described above by an antigen-antibody reaction.
  • This immune complex is formed by a sandwich immunoassay system using two or more kinds of antibodies.
  • the presence of the HBV antigen can be detected as a signal by a color development method or a chemiluminescence method using a labeling enzyme present in this immune complex.
  • HBV antigen can also be detected as a signal of the fluorescence.
  • the present invention provides the use of a kit for diagnosis of HBV infection using the above immunological detection method.
  • This diagnosis kit contains (a) a treatment agent for treating a sample containing HBV, comprising (1) an acidifying agent selected from the group of hydrochloric acid, sulfuric acid, trifluoroacetic acid and trichloroacetic acid, and (2) a cationic surfactant having an alkyl group of 12 or more carbon atoms and a tertiary amine or a quaternary ammonium salt within the same molecule and (b) a probe such as antibody that binds to an HBV antigen.
  • a treatment agent for treating a sample containing HBV comprising (1) an acidifying agent selected from the group of hydrochloric acid, sulfuric acid, trifluoroacetic acid and trichloroacetic acid, and (2) a cationic surfactant having an alkyl group of 12 or more carbon atoms and a tertiary amine or a quaternary ammonium salt within the same molecule and (b) a probe such as antibody that binds to an HBV anti
  • Concentration of acidifying agent To 100 ⁇ l of an HBV antigen-negative sample or each of HBV antigen-positive samples (#990277, #990544), 100 ⁇ l each of aqueous hydrochloric acid at various concentrations was added and the mixture was incubated for 10 min at room temperature. Then 100 ⁇ l of the mixture as samples for the assay was examined in the measurement method described below.
  • a mixture of monoclonal antibodies against HBV core-related antigens (HB44, HB114, and HB61 were mixed in a ratio of two to one to one) at a concentration of 4 ⁇ g/ml were added to each well and the plate was incubated overnight at 4°C.
  • Luminescence intensity was measured with a luminometer (DIA-IATRON, Luminous CT-9000D) and the result is shown in Figure 1 .
  • concentration of hydrochloric acid shown in Figure 1 is represented by the concentration at the treatment after mixing a sample with a treatment agent.
  • Immunoreactivity of HBV core-related antigens could hardly be detected in HBV antigen-positive samples (#990277, #990544) incubated in a solution not containing hydrochloric acid for 10 min at room temperature.
  • the immunoreactivity of HBV core-related antigens started to be observed when the concentration of hydrochloric acid at the treatment was 0.05 N or higher and reached a peak at from 0.25 to 1.0 N. Further, when the study was carried out using sulfuric acid in place of hydrochloric acid, almost the same result was obtained.
  • a surfactant that showed reactivity higher than the criterion for each sample in at least one sample of the three samples was judged to have an effect to detdct HBV core-related antigen sensitively.
  • an acidifying agent such as hydrochloric acid or sulfuric acid
  • amphoteric surfactants having an alkyl group and a tertiary amine or a quaternary ammonium salt within the same molecule which are not part of the invention and cationic surfactants having an alkyl group and a tertiary amine or a quaternary ammonium salt within the same molecule.
  • nonionic surfactants such as Triton X100 and Tween 20.
  • anionic surfactants which are not part of the invention, sodium dodecyl sulfate (SDS) and lithium dodecyl sulfate (LDS), at a concentration equal to or higher than 0.5% produced cloudiness during reaction with the samples, their effects could be confirmed by dissolving after addition of the reaction buffer containing the neutralizing agent.
  • a surfactant having a steroid skeleton such as CHAPS did not indicate an enhancement in reactivity.
  • sodium N-lauroyl sarcosine, deoxycholic acid, and the like were examined, but their solubility was not sufficient in the presence of the acidifying agent.
  • the present invention provides a simple and highly user-friendly sample treatment method for detection or quantification of HBV antigens in blood with high sensitivity and a method for detection or quantification of HBV with the use thereof and allows diagnosis of the presence or absence of HBV infection in blood and fast and accurate screening of blood for transfusion.
  • the present invention can also provide the use of a diagnostic kit and greatly contributes to efficiency enhancement of HBV antigen detection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP05741615A 2004-05-19 2005-05-19 Method of detecting hepatitis b virus Active EP1752768B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004149682 2004-05-19
PCT/JP2005/009158 WO2005111620A1 (ja) 2004-05-19 2005-05-19 Ｂ型肝炎ウィルスの検出方法

Publications (3)

Publication Number Publication Date
EP1752768A1 EP1752768A1 (en) 2007-02-14
EP1752768A4 EP1752768A4 (en) 2007-11-28
EP1752768B1 true EP1752768B1 (en) 2010-12-29

Family

ID=35394279

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05741615A Active EP1752768B1 (en) 2004-05-19 2005-05-19 Method of detecting hepatitis b virus

Country Status (8)

Country Link
US (2) US20090017443A1 (ja)
EP (1) EP1752768B1 (ja)
JP (1) JPWO2005111620A1 (ja)
KR (1) KR20070012838A (ja)
CN (1) CN1997895A (ja)
AT (1) ATE493659T1 (ja)
DE (1) DE602005025626D1 (ja)
WO (1) WO2005111620A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014115878A1 (ja) * 2013-01-28 2014-07-31 シスメックス株式会社 HBs抗原を検出するための試料の前処理方法およびその利用
JP6641841B2 (ja) * 2015-09-29 2020-02-05 富士レビオ株式会社 ヒトパルボウイルスｂ１９抗原の測定方法
WO2018047793A1 (ja) * 2016-09-06 2018-03-15 富士レビオ株式会社 腫瘍マーカーの測定方法及び測定試薬
JP7138627B2 (ja) * 2017-05-17 2022-09-16 富士レビオ株式会社 インスリンの測定方法及び測定試薬
CN111108193A (zh) 2017-09-18 2020-05-05 拜耳医药保健有限公司 使用n-甲基葡糖酰胺及其衍生物灭活病毒的方法
CN109870581B (zh) 2017-12-04 2021-05-04 厦门万泰凯瑞生物技术有限公司 一种定量检测HBsAg的试剂盒及方法
JP2019152666A (ja) * 2018-03-02 2019-09-12 富士レビオ株式会社 ジカウイルスを検出する方法及びキット
IL277890B2 (en) * 2018-04-11 2024-03-01 Regeneron Pharma Methods for quantification of IL-33
JP6426873B1 (ja) * 2018-08-06 2018-11-21 積水メディカル株式会社 マイコプラズマ・ニューモニエの免疫学的検出方法
WO2021060450A1 (ja) 2019-09-27 2021-04-01 富士レビオ株式会社 Ｂ型肝炎ウイルスコア関連抗原のイムノアッセイ及びそのためのキット
CN110954692A (zh) * 2019-12-20 2020-04-03 蓝怡科技集团股份有限公司 一种还原剂缓冲液及其制备方法和应用
WO2023013725A1 (ja) * 2021-08-06 2023-02-09 株式会社先端生命科学研究所 サイログロブリンのイムノアッセイ及びそのためのキット

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1308730A1 (en) * 2000-08-11 2003-05-07 Advanced Life Science Institute, Inc. Method of detecting or assaying hbv

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE92633T1 (de) * 1988-05-11 1993-08-15 Abbott Lab Verfahren zur erhoehung der spezifizitaet in kompetitiven immuntests.
JPH0850133A (ja) 1994-08-05 1996-02-20 Toray Ind Inc 免疫化学的測定方法
KR960023066A (ko) * 1994-12-10 1996-07-18 성재갑 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법
JP3176570B2 (ja) * 1997-08-04 2001-06-18 株式会社先端生命科学研究所 Ｈｃｖの検出又は測定方法
CA2267207C (en) * 1997-08-04 2008-10-28 Tonen Corporation Methods for detecting or assaying virus
BR9906660A (pt) * 1998-07-30 2000-08-29 Advanced Life Science Inst Inc Processo para medir vìrus da hepatite c
JP2000105233A (ja) * 1998-09-29 2000-04-11 Sekisui Chem Co Ltd 小粒子化ＨＢｓ抗原の調製法並びにこれを用いた免疫測定試薬の製造方法、免疫測定試薬及び免疫測定方法
WO2002010744A1 (fr) * 2000-08-01 2002-02-07 International Reagents Corporation Procede pour pretraiter un echantillon
EP1535927B1 (en) 2002-09-06 2010-07-14 Advanced Life Science Institute, Inc. Hbv precore protein capable of forming particles
CN101892199A (zh) * 2003-10-28 2010-11-24 株式会社先端生命科学研究所 丙型肝炎病毒的检测方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1308730A1 (en) * 2000-08-11 2003-05-07 Advanced Life Science Institute, Inc. Method of detecting or assaying hbv

Also Published As

Publication number Publication date
EP1752768A1 (en) 2007-02-14
DE602005025626D1 (de) 2011-02-10
US20100291546A1 (en) 2010-11-18
US20090017443A1 (en) 2009-01-15
CN1997895A (zh) 2007-07-11
ATE493659T1 (de) 2011-01-15
WO2005111620A1 (ja) 2005-11-24
EP1752768A4 (en) 2007-11-28
KR20070012838A (ko) 2007-01-29
JPWO2005111620A1 (ja) 2008-03-27

Similar Documents

Publication Publication Date Title
EP1752768B1 (en) Method of detecting hepatitis b virus
EP1801591B1 (en) Methods for detection or measurement of viruses
JP3510232B2 (ja) ウイルスの検出又は測定方法
JP6348553B2 (ja) ＨＢｓ抗原を検出するための前処理用試薬キットおよびＨＢｓ抗原検出用試薬キット
WO2008003236A1 (fr) Procédé de détection conjointe de l'antigène pres1 et de l'antigène de noyau de vhb, coffret d'expérimentation, substrat solide et solution de lyse de virus
EP1691198B1 (en) Method of detecting hepatitis c virus
US11454632B2 (en) Assay method and assay kit for hepatitis B virus S antigen
CN112526136B (zh) 一种联合检测乙型肝炎病毒核心相关抗原的样本预处理液及试剂盒
JP7308914B2 (ja) ウイルス抗原の血清学的検出方法
KR102390761B1 (ko) HBsAg의 정량적 검출을 위한 키트 및 방법
JP3176570B2 (ja) Ｈｃｖの検出又は測定方法
CN117074680A (zh) 一种乙型肝炎病毒核心相关抗原检测的样本前处理试剂及试剂盒
CA2491918C (en) Methods for detecting or assaying virus
JP6513189B2 (ja) 間接ＥＬＩＳＡを利用するヒトＦｃ包含タンパク質の力価測定キット及びこれを利用したＦｃ包含タンパク質の力価測定方法
JP2021165643A (ja) 高感度な抗ｈｂｖ抗体の検出方法
JP2001224371A (ja) Ｈｃｖの検出又は測定方法
JP2011106834A (ja) 免疫測定方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/53 20060101ALI20071018BHEP

Ipc: G01N 33/576 20060101AFI20071018BHEP

Ipc: G01N 33/543 20060101ALI20071018BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20071030

17Q First examination report despatched

Effective date: 20080319

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602005025626

Country of ref document: DE

Date of ref document: 20110210

Kind code of ref document: P

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005025626

Country of ref document: DE

Effective date: 20110210

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20101229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20101229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110329

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110429

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110429

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110409

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20110930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110531

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005025626

Country of ref document: DE

Effective date: 20110930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110531

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110531

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110519

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110519

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602005025626

Country of ref document: DE

Representative=s name: WINTER, BRANDL, FUERNISS, HUEBNER, ROESS, KAIS, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602005025626

Country of ref document: DE

Owner name: ADVANCED LIFE SCIENCE INSTITUTE, INC., HACHIOJ, JP

Free format text: FORMER OWNER: ADVANCED LIFE SCIENCE INSTITUTE, INC., WAKO, SAITAMA, JP

Ref country code: DE

Ref legal event code: R082

Ref document number: 602005025626

Country of ref document: DE

Representative=s name: WINTER, BRANDL - PARTNERSCHAFT MBB, PATENTANWA, DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: CA

Effective date: 20170915

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230528

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230526

Year of fee payment: 19

Ref country code: FR

Payment date: 20230525

Year of fee payment: 19

Ref country code: DE

Payment date: 20230519

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230523

Year of fee payment: 19